New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
04:55 EDTLGND, LGND, LGND, MDCO, MDCO, MDCO, ESRX, ESRX, ESRX, NPSP, NPSP, NPSP, BDSI, BDSI, BDSI, FEIC, FEIC, FEIC, HUM, HUM, HUM, IDIX, IDIX, IDIX, SYK, SYK, SYK, STE, STE, STE, PRTA, PRTA, PRTABofA/Merrill to hold a conference
2014 Healthcare Conference to be held in Las Vegas on May 13-15.
News For LGND;STE;SYK;IDIX;HUM;FEIC;BDSI;NPSP;ESRX;MDCO;PRTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 17, 2014
10:47 EDTNPSPNPS halted for volatility after Bloomberg says Shire considers bid
Subscribe for More Information
December 16, 2014
08:22 EDTESRXExpress Scripts CFO change a 'modest' concern, says Leerink
Subscribe for More Information
07:47 EDTESRXExpress Scripts new CFO experience reassuring, says Oppenheimer
Subscribe for More Information
December 15, 2014
18:30 EDTPRTAOn The Fly: After Hours Movers
UP AFTER EARNINGS: VeriFone Systems (PAY), up 1.5%. ALSO HIGHER: Prothena (PRTA), up 10.7% after receiving FDA fast track designation for NEOD001... Boeing (BA), up 2.3% after increasing dividend by 25% and authorizing a $12B share repurchase plan... Yamana Gold (AUY), up 4.6% after reporting new discoveries at Chapada, El Penon. LOWER: Abraxas Petroleum (AXAS), down 2% after reporting fourth quarter volume guidance and fiscal 2015 production guidance.
16:40 EDTESRXExpress Scripts backs FY14 EPS view $4.86-$4.90, consensus $4.88
Subscribe for More Information
16:39 EDTESRXExpress Scripts increases share repurchase authorization by 65M shares
Subscribe for More Information
16:37 EDTESRXExpress Scripts CFO Cathy Smith leaving company
Subscribe for More Information
16:09 EDTPRTAProthena receives FDA fast track designation for NEOD001
Subscribe for More Information
09:01 EDTHUMHumana appoints Cynthia Zipperle as Chief Accounting Officer
Subscribe for More Information
07:40 EDTESRXExpress Scripts price target raised to $96 from $82 at UBS
Subscribe for More Information
December 12, 2014
13:52 EDTHUMLeerink healthcare services analyst holds an analyst/industry conference call
Subscribe for More Information
December 11, 2014
08:02 EDTMDCOAlnylam, The Medicines Co. announce initiation of Phase 1 ALN-PCSsc trial
Subscribe for More Information
December 10, 2014
14:45 EDTHUMDeal would block payments to health insurance companies, The Hill says
Subscribe for More Information
10:56 EDTHUMSaint Luke's enters into agreement with Humana
Saint Luke’s Health System and Humana announced an agreement through which Humana will offer a new health insurance plan to Missourians purchasing insurance through the Missouri Health Insurance Marketplace, also known as an exchange.
December 8, 2014
15:21 EDTFEICFEI Company management to meet with Sidoti
Subscribe for More Information
12:42 EDTSYKStryker resolves government investigation of OtisMed matter
Subscribe for More Information
12:25 EDTMDCOAntibiotic makers rise after Merck agrees to buy Cubist
Subscribe for More Information
11:30 EDTESRXLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
10:11 EDTMDCOHigh option volume stocks
Subscribe for More Information
07:01 EDTBDSIBioDelivery Sciences completes randomization in trial of clonidine topical gel
BioDelivery Sciences announced that it has completed the randomization of all patients in BDSI's ongoing initial pivotal Phase 3 clinical trial for Clonidine Topical Gel for the treatment of painful diabetic neuropathy. BDSI anticipates that topline results of the study will be available by the end of March 2015. The Phase 3 trial is a multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of Clonidine Topical Gel in the treatment of pain associated with PDN. In the trial, known as the RHAPSODY Study, subjects were randomized to receive either Clonidine Topical Gel or a placebo gel. Two hundred and sixty three adult subjects were randomized into the 12 week double-blind treatment phase of the study. This is the first of two pivotal trials that would be required for submission of a New Drug Application to the U.S. Food and Drug Administration. FDA has granted Fast Track designation for the program, which recognizes the need of developing new therapies for this serious condition. BDSI plans to begin the second Phase 3 study during the first quarter of 2015.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use